Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 7/20 | 0.52 |
| ▸ | GART | P22102 | 2/20 | 0.52 |
| ▸ | ATIC | P31939 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658559 | 1.00 | TYMS (0.76) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL29853494 | 1.00 | TYMS (0.76) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL14947039 | 0.94 | TYMS (0.67) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL14264584 | 0.92 | TYMS (0.67) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL20386936 | 0.91 | TYMS (0.61) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL34465311 | 0.90 | TYMS (0.65) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL26058996 | 0.90 | TYMS (0.61) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL973923 | 0.90 | TYMS (0.76) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL14431105 | 0.90 | TYMS (0.60) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL16965374 | 0.90 | TYMS (0.60) | TYMSKDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108578705-B | Folic acid grafted fullerol adriamycin-loaded prodrug and preparation method and application thereof | 浙江医药高等专科学校 | 2021-10-15 | — | — | CN | claimed |
| US-20230285561-A1 | Targeting Microbubbles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-09-14 | — | — | US | disclosed |
| US-20230285561-A1 | Targeting Microbubbles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-09-14 | — | — | US | disclosed |
| US-11642410-B2 | Targeting microbubbles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642410-B2 | Targeting microbubbles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-05-09 | — | — | US | disclosed |
| CN-114306356-A | Folic acid/cis-aconitic anhydride bond adriamycin/human serum albumin (FA/CAD/HSA) composition and preparation method and application thereof | 兰州大学 | 2022-04-12 | — | — | CN | disclosed |
| US-11224655-B2 | Targeting microbubbles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-01-18 | — | — | US | disclosed |
| CN-108578705-B | Folic acid grafted fullerol adriamycin-loaded prodrug and preparation method and application thereof | 浙江医药高等专科学校 | 2021-10-15 | — | — | CN | disclosed |
| US-20210221835-A1 | CARBON-MONOXIDE-RELEASING MOLECULES AND THERAPEUTIC APPLICATIONS THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210128516-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | NOVARTIS AG (CH) | 2021-05-06 | — | — | US | disclosed |
| US-8110179-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110129417-A1 | ADMINISTRABLE COMPOSITIONS | UNIVERSITY OF SYDNEY (AU) | 2011-06-02 | — | — | US | disclosed |
| EP-2291175-A1 | ADMINISTRABLE COMPOSITIONS | THE UNIVERSITY OF SYDNEY (AU) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009137890-A1 | ADMINISTRABLE COMPOSITIONS | THE UNIVERSITY OF SYDNEY (AU) | 2009-11-19 | — | — | WO | disclosed |
| US-20080213379-A1 | Tumor environment-induced ligand-expressing nanocarrier system | BAE YOU HAN | 2008-09-04 | — | — | US | disclosed |
| US-7371781-B2 | Tumor environment-induced ligand-expressing nanocarrier system | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7270808-B2 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7270808-B2 | Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity | INSERT THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11224655-B2 | Targeting microbubbles | PGF, EDNRB, FLT4 | TYMS 1681/4885KDM4E 3320/4885MEN1 1071/4885 |
| US-20210221835-A1 | CARBON-MONOXIDE-RELEASING MOLECULES AND THERAPEUTIC APPLICATIONS THEREOF | MB, HMOX1, CYC1 | TYMS 2214/4885KDM4E 1031/4885MEN1 2719/4885 |
| US-20080058427-A1 | Cyclodextrin-based polymers for therapeutics delivery | DDOST, DSC1, SI | TYMS 1005/4885KDM4E 3582/4885MEN1 4082/4885 |
| US-20210128516-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | SDCBP, DDOST, CD47 | TYMS 1034/4885KDM4E 3113/4885MEN1 4023/4885 |
| US-20230285561-A1 | Targeting Microbubbles | PGF, EDNRB, FLT4 | TYMS 1681/4885KDM4E 3320/4885MEN1 1071/4885 |
| US-20110129417-A1 | ADMINISTRABLE COMPOSITIONS | CYP2B6, LPXN, ELOVL6 | TYMS 2649/4885KDM4E 3863/4885MEN1 3503/4885 |
| US-11642410-B2 | Targeting microbubbles | PGF, EDNRB, FLT4 | TYMS 1681/4885KDM4E 3320/4885MEN1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.